Clofazimine : current status and future prospects

dc.contributor.authorCholo, Moloko C.
dc.contributor.authorSteel, Helen Carolyn
dc.contributor.authorFourie, Petrus Bernardus
dc.contributor.authorGermishuizen, Willem Andreas
dc.contributor.authorAnderson, Ronald
dc.date.accessioned2012-03-14T11:31:01Z
dc.date.available2013-02-28T00:20:03Z
dc.date.issued2012-02
dc.description.abstractClofazimine, a lipophilic riminophenazine antibiotic, possesses both antimycobacterial and anti-inflammatory activities. However, its efficacy has been demonstrated only in the treatment of leprosy, not in human tuberculosis, despite the fact that this agent is impressively active in vitro against multidrug-resistant strains of Mycobacterium tuberculosis. Recent insights into novel targets and mechanisms of antimicrobial and antiinflammatory activity coupled with the acquisition of innovative drug delivery technologies have, however, rekindled interest in clofazimine as a potential therapy for multidrug- and extensively multidrug-resistant tuberculosis in particular, as well as several autoimmune diseases. The primary objective of this review is to critically evaluate these recent developments and to assess their potential impact on improving the therapeutic efficacy and versatility of clofazimine.en_US
dc.description.sponsorshipThe South African Medical Research Council. Research into the spray-dried formulations of clofazimine is supported by the K-RITH collaborative grant (Howard Hughes Medical Institute and the University of KwaZulu-Natal).en_US
dc.description.urihttp://jac.oxfordjournals.org/en_US
dc.identifier.citationCholo, MC, Steel, HC, Fourie, PB, Germishuizen, WA & Anderson, R 2012, 'Clofazimine: current status and future prospects', Journal of Antimicrobial Chemotherapy, vol. 67, no. 2, pp. 290-298.en_US
dc.identifier.issn0305-7453 (print)
dc.identifier.issn1460-2091 (online)
dc.identifier.other10.1093/jac/dkr444
dc.identifier.urihttp://hdl.handle.net/2263/18427
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.rights© The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Journal of Antimicrobial Chemotherapy following peer review. The definitive publisher-authenticated version of Cholo, MC, Steel, HC, Fourie, PB, Germishuizen, WA & Anderson, R 2012, 'Clofazimine: current status and future prospects', Journal of Antimicrobial Chemotherapy, vol. 67, no. 2, pp. 290-298 is available online at: jac.oxfordjournals.org/content/67/2/290. This article is embargoed by the publisher until February 2013.en_US
dc.subjectAnti-inflammatory activityen_US
dc.subjectLeprosyen_US
dc.subjectLysophospholipidsen_US
dc.subjectMembrane destabilizationen_US
dc.subjectMycobacteriaen_US
dc.subjectPotassium transportersen_US
dc.subjectReactive oxygen speciesen_US
dc.subjectRedox cyclingen_US
dc.subjectSpray-dryingen_US
dc.subjectTuberculosisen_US
dc.subjectT lymphocytesen_US
dc.subject.lcshTuberculosis -- Vaccinationen
dc.titleClofazimine : current status and future prospectsen_US
dc.typePostprint Articleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Cholo_Clofazimine(2012).pdf
Size:
1.11 MB
Format:
Adobe Portable Document Format
Description:
Postprint Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: